epafenac and Prevention of CME after Cataract Surgery in Patients Receiving Latanoprost: A Randomized Controlled Trial

Phase 3

Recruiting

• Conditions: Cystoid macular oedema; CME; Prostaglandin; Latanoprost; Nepafenac; NSAIDs; Cataract surgery; Phacoemulsification; OCT; Optical coherence tomography

• Registration Number: TCTR20110000013
• Lead Sponsor: Glaucoma Research Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-05-06
• Study Completion: 2011-12-23
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Eyes receiving 0.005% Latanoprost at least 1-month prior to a planned phacoemulsification with PC-IOL implantation; age over 18 years

Exclusion Criteria

history of intra-ocular inflammation; CSME, or macular oedema of any aetiology; proliferative
diabetic retinopathy; retinitis pigmentosa; prior vitreo-retinal surgery; pregnancy;
known/suspicious allergy to NSAIDs/Prostaglandin analogues; physical/mental/intellectual
disabilities preventing from understanding and complying to protocol

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of post-operative CME Up to 10 weeks accumulatively post-operative Optical Coherence Tomography

Secondary Outcome Measures

Name	Time	Method
Occurrence of post-cataract surgery CME in non-intervention group Up to 10 weeks accumulatively post-operative Optical Coherence Tomography